Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.
Christopher Holroyd(Southampton General Hospital), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Lucy Anne Parker(Universitat de Miguel Hernández d'Elx), Nicholas C. Harvey(University Hospital Southampton NHS Foundation Trust), Caron Underhill(University Hospital Southampton NHS Foundation Trust), Elaine Dennison(MRC Lifecourse Epidemiology Unit), Sarah Bennett, Cyrus Cooper(University Hospital Southampton NHS Foundation Trust), Brian Davidson(University Hospital Southampton NHS Foundation Trust), Ray Armstrong(University Hospital Southampton NHS Foundation Trust), Jalaa Zarroug(University Hospital Southampton NHS Foundation Trust)
PubMed
April 24, 2018
Cited by 17
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k